image
Healthcare - Medical - Devices - NASDAQ - US
$ 10.95
-0.725 %
$ 303 M
Market Cap
-15.64
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CLPT stock under the worst case scenario is HIDDEN Compared to the current market price of 10.9 USD, ClearPoint Neuro, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CLPT stock under the base case scenario is HIDDEN Compared to the current market price of 10.9 USD, ClearPoint Neuro, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CLPT stock under the best case scenario is HIDDEN Compared to the current market price of 10.9 USD, ClearPoint Neuro, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CLPT

image
$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
31.4 M REVENUE
31.04%
-19.7 M OPERATING INCOME
12.03%
-18.9 M NET INCOME
14.37%
-8.95 M OPERATING CASH FLOW
34.77%
-275 K INVESTING CASH FLOW
-3.07%
6.19 M FINANCING CASH FLOW
1990.88%
7.77 M REVENUE
-4.32%
-5.6 M OPERATING INCOME
-8.35%
-5.39 M NET INCOME
-8.28%
-1.24 M OPERATING CASH FLOW
-3.67%
-263 K INVESTING CASH FLOW
-2091.67%
37 K FINANCING CASH FLOW
100.37%
Balance Sheet ClearPoint Neuro, Inc.
image
Current Assets 33.4 M
Cash & Short-Term Investments 20.1 M
Receivables 4.71 M
Other Current Assets 8.55 M
Non-Current Assets 5.83 M
Long-Term Investments 0
PP&E 5.09 M
Other Non-Current Assets 735 K
51.30 %12.03 %21.81 %12.99 %Total Assets$39.2m
Current Liabilities 10.4 M
Accounts Payable 1.34 M
Short-Term Debt 557 K
Other Current Liabilities 8.46 M
Non-Current Liabilities 3.45 M
Long-Term Debt 3.01 M
Other Non-Current Liabilities 436 K
9.71 %4.04 %61.28 %21.82 %3.16 %Total Liabilities$13.8m
EFFICIENCY
Earnings Waterfall ClearPoint Neuro, Inc.
image
Revenue 31.4 M
Cost Of Revenue 12.3 M
Gross Profit 19.1 M
Operating Expenses 38.9 M
Operating Income -19.7 M
Other Expenses -832 K
Net Income -18.9 M
40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)31m(12m)19m(39m)(20m)832k(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
60.92% GROSS MARGIN
60.92%
-62.91% OPERATING MARGIN
-62.91%
-60.25% NET MARGIN
-60.25%
-74.50% ROE
-74.50%
-48.26% ROA
-48.26%
-67.18% ROIC
-67.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ClearPoint Neuro, Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -18.9 M
Depreciation & Amortization 1.9 M
Capital Expenditures -275 K
Stock-Based Compensation 6.91 M
Change in Working Capital 1.4 M
Others -1.49 M
Free Cash Flow -9.22 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ClearPoint Neuro, Inc.
image
Wall Street analysts predict an average 1-year price target for CLPT of $19.8 , with forecasts ranging from a low of $9 to a high of $30 .
CLPT Lowest Price Target Wall Street Target
9 USD -17.81%
CLPT Average Price Target Wall Street Target
19.8 USD 80.82%
CLPT Highest Price Target Wall Street Target
30 USD 173.97%
Price
Max Price Target
Min Price Target
Average Price Target
3030252520201515101055May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership ClearPoint Neuro, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical services should provide the drug delivery business with a boost within the next 18 months. ClearPoint also continues to control its cash burn, despite continuing to make investments in future growth. seekingalpha.com - 1 month ago
ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings. seekingalpha.com - 1 month ago
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Misses Revenue Estimates ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago. zacks.com - 1 month ago
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended December 31, 2024. 2024 Full Year and Fourth Quarter Highlights Reported fourth quarter 2024 revenue of $7.8 million, a 14% year-over-year increase compared with the fourth quarter of 2023; Reported revenue of $31.4 million for the full year 2024, an increase of 31% over 2023 and representing the tenth consecutive year of growth; Overall product revenue, including biologics and drug delivery, grew 76% to $18.6 million for the full year as a result of the SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System and partner progression in clinical trials; Activated six new global centers in the fourth quarter for a total of 25 new centers in 2024, approximately three times our historic activation rate; Continued patient enrollment in numerous cell and gene therapy trials for partners selected in FDA expedited review programs across multiple indications; Full early repayment of the principal amount and interest on a $10 million convertible note leaving the Company with no outstanding debt; Quarterly operational cash burn of $1.2 million, bringing total 2024 operational cash burn of $9.0 million, a reduction of 35% versus 2023; and Reported cash and cash equivalents totaling $20.1 million as of December 31, 2024. accessnewswire.com - 1 month ago
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025 SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 fourth quarter and full year on Wednesday, February 26th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 fourth quarter and full year results on Wednesday, February 26th, at 4:30 p.m. accessnewswire.com - 2 months ago
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) approval for the SmartFlow Neuro Cannula. The SmartFlow Cannula was previously cleared under the Medical Device Directive 93/42/EEC (MDD) and has now successfully achieved the more rigorous EU MDR certification well ahead of the 2027 deadline for Class III devices. accessnewswire.com - 2 months ago
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0 ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States. zacks.com - 2 months ago
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0 SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its ClearPoint Navigation Software Version 3.0. "As we prepare for the wave of new patients that will be treated with cell and gene therapies in the years ahead, it is crucial that ClearPoint helps healthcare providers be ready by providing simplified workflows, offering solutions to increase surgical capacity and expanding access to our hardware and software," commented Joe Burnett, President and CEO at ClearPoint Neuro. accessnewswire.com - 2 months ago
ClearPoint Neuro (CLPT) Surges 22.5%: Is This an Indication of Further Gains? ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 2 months ago
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains. zacks.com - 3 months ago
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. accesswire.com - 5 months ago
ClearPoint Neuro: Near-Term Volatility Is No Concern ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near term due to the company's size and the immaturity of growth initiatives. ClearPoint's margins are improving, and cash burn is minimal, which should ease concerns about dilution. seekingalpha.com - 5 months ago
8. Profile Summary

ClearPoint Neuro, Inc. CLPT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 303 M
Dividend Yield 0.00%
Description ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Contact 120 S. Sierra Avenue, Solana Beach, CA, 92075 https://www.clearpointneuro.com
IPO Date May 22, 2012
Employees 115
Officers Mr. Mazin Sabra Chief Operating Officer Mr. Joseph Michael Burnett President, Chief Executive Officer & Director Ms. Ellisa Cholapranee J.D. General Counsel & Secretary Mr. Jeremy Stigall Chief Business Officer Mr. Danilo D'Alessandro Chief Financial Officer